Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19 : Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
© 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology..
OBJECTIVE: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.
METHODS: Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.
RESULTS: One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.
CONCLUSION: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
ACR open rheumatology - 4(2022), 11 vom: 17. Nov., Seite 948-953 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 14.11.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/acr2.11495 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345190122 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345190122 | ||
| 003 | DE-627 | ||
| 005 | 20231226024513.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/acr2.11495 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345190122 | ||
| 035 | |a (NLM)36000538 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jatuworapruk, Kanon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19 |b Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. | ||
| 520 | |a OBJECTIVE: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes | ||
| 520 | |a METHODS: Data on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death | ||
| 520 | |a RESULTS: One hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities | ||
| 520 | |a CONCLUSION: This cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Montgomery, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Gianfrancesco, Milena |e verfasserin |4 aut | |
| 700 | 1 | |a Conway, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Durcan, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Graef, Elizabeth R |e verfasserin |4 aut | |
| 700 | 1 | |a Jayatilleke, Aruni |e verfasserin |4 aut | |
| 700 | 1 | |a Keen, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Kilian, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Kristen |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona, Loreto |e verfasserin |4 aut | |
| 700 | 1 | |a Cogo, Adriana Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte-García, Alí |e verfasserin |4 aut | |
| 700 | 1 | |a Gossec, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Hasseli, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Hyrich, Kimme L |e verfasserin |4 aut | |
| 700 | 1 | |a Langlois, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Lawson-Tovey, Saskia |e verfasserin |4 aut | |
| 700 | 1 | |a Malcata, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Mateus, Elsa F |e verfasserin |4 aut | |
| 700 | 1 | |a Schafer, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Scirè, Carlo Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Sigurdardottir, Valgerdur |e verfasserin |4 aut | |
| 700 | 1 | |a Sparks, Jeffrey A |e verfasserin |4 aut | |
| 700 | 1 | |a Strangfeld, Anja |e verfasserin |4 aut | |
| 700 | 1 | |a Xavier, Ricardo M |e verfasserin |4 aut | |
| 700 | 1 | |a Bhana, Suleman |e verfasserin |4 aut | |
| 700 | 1 | |a Gore-Massy, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Hausmann, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Liew, Jean W |e verfasserin |4 aut | |
| 700 | 1 | |a Sirotich, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Sufka, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Wallace, Zach |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Pedro M |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdany, Jinoos |e verfasserin |4 aut | |
| 700 | 1 | |a Grainger, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Philip C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACR open rheumatology |d 2019 |g 4(2022), 11 vom: 17. Nov., Seite 948-953 |w (DE-627)NLM295459263 |x 2578-5745 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2022 |g number:11 |g day:17 |g month:11 |g pages:948-953 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/acr2.11495 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2022 |e 11 |b 17 |c 11 |h 948-953 | ||